Premium
Tigecycline for Treatment of Pneumonia and Empyema Caused by Carbapenemase‐Producing Klebsiella pneumoniae
Author(s) -
Daly Michael W.,
Riddle David J.,
Ledeboer Nathan A.,
Dunne W. Michael,
Ritchie David J.
Publication year - 2007
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.27.7.1052
Subject(s) - tigecycline , klebsiella pneumoniae , medicine , pneumonia , empyema , antibiotics , microbiology and biotechnology , klebsiella pneumonia , carbapenem resistant enterobacteriaceae , intensive care medicine , biology , pseudomonas aeruginosa , surgery , bacteria , biochemistry , genetics , escherichia coli , gene
Strains of Klebsiella pneumoniae that produce one of three possible carbapenemases—KPC—have recently been identified with increasing frequency among isolates recovered from patients residing along the East Coast of the United States, particularly within the New York City metropolitan region. These strains have exhibited resistance to multiple antibiotic classes, including carbapenem agents. We report a case of nosocomial pneumonia and empyema caused by a KPC‐producing isolate of K. pneumoniae at a large midwestern U.S. tertiary care facility in which the patient was treated with tigecycline. Although the pneumonia was treated successfully, the empyema recurred in association with a treatment‐emergent tigecycline minimum inhibitory concentration (MIC) increase from 0.75 to 2 μg/ml. Clinicians should be aware of the potential occurrence of this treatment‐emergent MIC increase, especially in the setting of sustained tigecycline therapy. In addition, the emergence of carbapenem‐resistant Enterobacteriaceae reinforces the importance of antibiotic stewardship and strict infection control practices.